Elutia (ELUT) Competitors $3.22 +0.02 (+0.59%) As of 02/21/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ELUT vs. ATAI, RVNC, PRME, ESPR, RGNX, TRML, MBX, ACB, TERN, and FHTXShould you be buying Elutia stock or one of its competitors? The main competitors of Elutia include Atai Life Sciences (ATAI), Revance Therapeutics (RVNC), Prime Medicine (PRME), Esperion Therapeutics (ESPR), REGENXBIO (RGNX), Tourmaline Bio (TRML), MBX Biosciences (MBX), Aurora Cannabis (ACB), Terns Pharmaceuticals (TERN), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry. Elutia vs. Atai Life Sciences Revance Therapeutics Prime Medicine Esperion Therapeutics REGENXBIO Tourmaline Bio MBX Biosciences Aurora Cannabis Terns Pharmaceuticals Foghorn Therapeutics Atai Life Sciences (NASDAQ:ATAI) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, community ranking, analyst recommendations, dividends, media sentiment, institutional ownership and profitability. Is ATAI or ELUT more profitable? Atai Life Sciences has a net margin of 0.00% compared to Elutia's net margin of -218.72%. Elutia's return on equity of 0.00% beat Atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Atai Life SciencesN/A -65.75% -52.71% Elutia -218.72%N/A -142.61% Do analysts prefer ATAI or ELUT? Atai Life Sciences currently has a consensus target price of $9.00, suggesting a potential upside of 352.26%. Elutia has a consensus target price of $10.00, suggesting a potential upside of 210.56%. Given Atai Life Sciences' higher probable upside, equities analysts clearly believe Atai Life Sciences is more favorable than Elutia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in ATAI or ELUT? 28.4% of Atai Life Sciences shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 31.2% of Atai Life Sciences shares are held by company insiders. Comparatively, 40.8% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor ATAI or ELUT? In the previous week, Atai Life Sciences had 5 more articles in the media than Elutia. MarketBeat recorded 6 mentions for Atai Life Sciences and 1 mentions for Elutia. Atai Life Sciences' average media sentiment score of 0.66 beat Elutia's score of 0.66 indicating that Atai Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elutia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, ATAI or ELUT? Elutia has higher revenue and earnings than Atai Life Sciences. Atai Life Sciences is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtai Life Sciences$310K1,077.17-$40.22M-$0.81-2.46Elutia$24.75M4.50-$37.66M-$2.61-1.23 Which has more risk and volatility, ATAI or ELUT? Atai Life Sciences has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Elutia has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Does the MarketBeat Community favor ATAI or ELUT? Atai Life Sciences received 323 more outperform votes than Elutia when rated by MarketBeat users. However, 100.00% of users gave Elutia an outperform vote while only 66.47% of users gave Atai Life Sciences an outperform vote. CompanyUnderperformOutperformAtai Life SciencesOutperform Votes33366.47% Underperform Votes16833.53% ElutiaOutperform Votes10100.00% Underperform VotesNo Votes SummaryAtai Life Sciences beats Elutia on 10 of the 16 factors compared between the two stocks. Get Elutia News Delivered to You Automatically Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELUT vs. The Competition Export to ExcelMetricElutiaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$110.60M$3.12B$5.85B$9.15BDividend YieldN/A1.56%4.76%3.85%P/E RatioN/A10.3116.5114.19Price / Sales4.50327.11450.0276.60Price / CashN/A168.8538.0134.95Price / Book-1.943.687.644.63Net Income-$37.66M-$71.72M$3.18B$245.69M7 Day Performance14.18%-2.46%-1.95%-2.68%1 Month PerformanceN/A-0.25%-0.23%-2.16%1 Year Performance-4.17%-12.31%16.69%12.90% Elutia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELUTElutia3.5984 of 5 stars$3.22+0.6%$10.00+210.6%-13.0%$110.60M$24.75M0.00180News CoverageATAIAtai Life Sciences3.114 of 5 stars$2.30+1.3%$9.00+291.3%+5.9%$385.94M$310,000.00-2.8480Insider TradeNews CoverageGap UpHigh Trading VolumeRVNCRevance Therapeutics4.1959 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Analyst ForecastPRMEPrime Medicine2.5356 of 5 stars$2.84+9.2%$13.13+362.1%-65.1%$372.49MN/A-1.39234News CoverageESPREsperion Therapeutics4.4488 of 5 stars$1.86-0.5%$6.75+262.9%-30.1%$366.49M$116.33M-2.91200Gap DownRGNXREGENXBIO3.914 of 5 stars$7.30-0.3%$33.45+358.3%-60.5%$361.64M$90.24M-1.45370Analyst RevisionTRMLTourmaline Bio1.7636 of 5 stars$13.83+5.7%$54.00+290.5%-66.2%$354.60MN/A-4.9044MBXMBX Biosciences2.5939 of 5 stars$10.41+15.8%$37.25+257.8%N/A$347.90MN/A0.0036Insider TradeNews CoverageACBAurora Cannabis0.5205 of 5 stars$6.31-4.7%N/A+73.2%$346.17M$200.35M126.231,073Gap UpTERNTerns Pharmaceuticals4.4005 of 5 stars$4.06-0.5%$18.30+350.7%-50.4%$344.86MN/A-3.4440FHTXFoghorn Therapeutics2.7039 of 5 stars$6.13-0.5%$13.17+114.8%-12.4%$340.89M$34.15M-3.19120Positive News Related Companies and Tools Related Companies ATAI Competitors RVNC Competitors PRME Competitors ESPR Competitors RGNX Competitors TRML Competitors MBX Competitors ACB Competitors TERN Competitors FHTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELUT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elutia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
